clearside
biomedical
announces
clinical
data
presentations
retina
society
publication
data
diabetic
macular
edema
ophthalmology
retina
alpharetta
globe
newswire
clearside
biomedical
nasdaq
clsd
biopharmaceutical
company
dedicated
developing
delivering
treatments
restore
preserve
vision
people
serious
back
eye
diseases
announced
today
several
clinical
data
presentations
given
virtual
annual
scientific
meeting
retina
society
clearside
also
announced
data
company
phase
clinical
trial
diabetic
macular
edema
dme
published
ophthalmology
retina
accessed
trial
entitled
tybee
evaluated
investigational
drug
triamcinolone
acetonide
suprachoroidal
injectable
suspension
used
intravitreally
administered
aflibercept
patients
dme
evaluation
period
early
data
suggests
approved
xipere
administered
suprachoroidally
may
potential
reduce
treatment
burden
patients
primary
goal
clearside
deliver
targeted
treatments
patients
suffering
serious
retinal
diseases
said
thomas
ciulla
mba
chief
medical
officer
chief
development
officer
committed
educating
physicians
broader
retinal
community
programs
presentations
delivered
week
publication
work
dme
underscore
broad
scope
development
activities
suprachoroidal
injection
platform
continue
expand
pipeline
new
opportunities
indications
look
forward
starting
phase
clinical
trial
neovascular
macular
degeneration
wet
amd
title
suprachoroidal
axitinib
injectable
suspension
potential
therapy
neovascular
macular
degeneration
namd
authors
david
brown
viral
kansara
thomas
ciulla
conclusions
observed
well
tolerated
animal
species
evaluated
overt
signs
toxicity
sustained
high
exposure
observed
ocular
tissues
highest
concentration
found
tissues
sclera
choroid
retinal
pigment
epithelium
rpe
followed
retina
intrinsic
high
potency
inhibition
receptor
blockade
demonstrated
prolonged
duration
observed
pharmacokinetic
studies
well
pharmacodynamic
effect
multiple
animal
models
intended
targeted
therapy
affected
tissue
layers
via
suprachoroidal
injection
potential
therapy
wet
amd
title
post
hoc
analysis
clinical
suprachoroidal
injection
experience
across
indications
author
chris
henry
faculty
sponsor
amy
schefler
cherry
wan
barry
kapik
colette
hall
thomas
ciulla
conclusions
date
robust
aggregate
dataset
clinical
suprachoroidal
injections
mounting
evidence
pointing
potential
reliability
consistency
procedure
results
retrospective
analysis
demonstrated
robustness
suprachoroidal
injection
regardless
indications
two
needle
length
options
successfully
accommodated
anatomical
variations
across
patients
title
suprachoroidal
delivery
small
molecule
suspensions
nanoparticles
authors
judy
kim
viral
kansara
thomas
ciulla
conclusions
delivery
small
molecule
suspensions
may
provide
targeted
delivery
wide
variety
pharmacologic
agents
including
corticosteroids
tyrosine
kinase
inhibitors
tkis
complement
inhibitors
rpe
sclera
choroid
preclinical
models
compounds
promising
based
favorable
clinical
results
small
molecule
corticosteroid
macular
edema
associated
noninfectious
uveitis
testing
warranted
molecules
additionally
suprachoroidal
delivery
dna
gene
potential
retinal
gene
therapy
testing
warranted
title
suprachoroidally
delivered
dna
nanoparticles
transfect
chorioretinal
cells
primates
rabbits
authors
nancy
holekamp
viral
kansara
thomas
ciulla
conclusions
suprachoroidal
injections
dna
nanoparticles
may
address
several
unmet
needs
ocular
gene
delivery
dna
nanoparticles
relatively
compared
viral
gene
therapy
suprachoroidal
injection
facilitates
potential
repeat
dosing
fewer
safety
risks
compared
subretinal
injection
via
pars
plana
vitrectomy
surgery
addition
dna
nanoparticles
transfer
genes
beyond
capacity
viral
vectors
including
common
inherited
retinal
diseases
irds
stargardt
disease
usher
syndrome
additional
research
evaluating
suprachoroidal
injection
primates
delivery
therapeutic
transgene
needed
title
results
phase
peachtree
clinical
trial
systemic
therapy
efficacy
analysis
authors
pauline
merrill
thomas
ciulla
conclusions
post
hoc
results
corroborate
study
analyses
peachtree
trial
respect
best
corrected
visual
acuity
bcva
central
subfield
thickness
cst
showed
clinically
meaningful
relative
benefit
control
patients
receiving
systemic
immunosuppression
patients
receiving
systemic
immunosuppression
title
correlation
best
corrected
visual
acuity
central
subfield
thickness
macular
edema
due
retinal
vein
occlusion
diabetic
retinopathy
uveitis
authors
michael
ip
thomas
ciulla
conclusions
cohort
eyes
moderate
baseline
relationships
bcva
cst
patients
macular
edema
due
retinal
vein
occlusion
rvo
diabetic
macular
edema
dme
noninfectious
uveitis
also
moderate
relationships
bcva
cst
across
disease
states
respect
change
baseline
months
correlations
provide
context
around
use
cst
clinical
decision
making
title
visual
acuity
outcomes
endothelial
growth
factor
therapy
intensity
macular
edema
due
retinal
vein
occlusion
analysis
eyes
authors
thomas
ciulla
john
pollack
david
williams
conclusions
rvo
patients
macular
edema
experience
worse
visual
outcomes
compared
patients
randomized
controlled
trials
mean
change
visual
acuity
va
correlated
treatment
intensity
year
patients
better
va
presentation
tended
particularly
vulnerable
vision
loss
copies
presentations
available
clearside
website
publications
presentations
page
https
clearside
suprachoroidal
space
injection
platform
clearside
patented
proprietary
suprachoroidal
space
scs
injection
treatment
approach
offers
unprecedented
access
back
eye
disease
often
occurs
clearside
proprietary
scs
used
inject
wide
variety
drug
candidates
specifically
formulated
delivered
via
suprachoroidal
injection
company
unique
platform
inherently
flexible
intended
work
established
medications
new
formulations
medicines
well
future
innovations
gene
therapy
axitinib
injectable
suspension
axitinib
injectable
suspension
proprietary
suspension
axitinib
suprachoroidal
injection
axitinib
tyrosine
kinase
inhibitor
tki
currently
approved
treat
renal
cell
cancer
achieves
blockade
directly
inhibiting
vegf
high
potency
specificity
clearside
believes
broad
vegf
blockade
may
efficacy
advantages
existing
retinal
therapies
acting
different
level
angiogenesis
cascade
may
benefit
patients
respond
current
narrowly
focused
therapies
suprachoroidal
injection
proprietary
suspension
axitinib
demonstrated
meaningful
potential
preclinical
studies
multiple
species
preclinical
results
clearside
independent
investigators
shown
pharmacodynamic
effect
reduced
growth
experimental
neovascularization
decreased
fluorescein
leakage
suprachoroidal
administration
axitinib
potential
achieve
prolonged
duration
targeted
delivery
affected
tissue
layers
clearside
developing
therapy
treatment
wet
amd
triamcinolone
acetonide
suprachoroidal
injectable
suspension
triamcinolone
acetonide
suprachoroidal
injectable
suspension
formerly
known
proprietary
suspension
corticosteroid
triamcinolone
acetonide
formulated
administration
back
eye
investigated
treatment
macular
edema
associated
uveitis
clearside
patented
technology
designed
deliver
drug
suprachoroidal
space
located
choroid
outer
protective
layer
eye
known
sclera
suprachoroidal
injection
enables
rapid
adequate
dispersion
medicine
back
eye
offering
potential
medicine
act
longer
minimize
harm
surrounding
healthy
parts
eye
bausch
lomb
leading
global
eye
health
business
bausch
health
companies
bausch
health
nyse
tsx
bhc
exclusive
license
commercialization
development
xipere
united
states
canada
exclusive
options
right
commercialize
develop
xipere
europe
united
kingdom
australia
new
zealand
south
america
mexico
license
agreement
clearside
bausch
health
affiliate
arctic
vision
specialty
ophthalmology
company
based
china
exclusive
license
commercialization
development
xipere
greater
china
south
korea
clearside
biomedical
clearside
biomedical
biopharmaceutical
company
dedicated
developing
delivering
treatments
restore
preserve
vision
people
serious
back
eye
diseases
clearside
proprietary
scs
targets
suprachoroidal
space
offers
unique
access
macula
retina
choroid
disease
often
occurs
company
scs
injection
platform
inherently
flexible
procedure
intended
provide
targeted
delivery
site
disease
work
established
new
formulations
medications
well
future
therapeutic
innovations
gene
therapy
information
please
visit
cautionary
note
regarding
statements
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
may
identified
words
believe
expect
may
plan
potential
similar
expressions
based
clearside
current
beliefs
expectations
statements
include
statements
regarding
development
potential
benefits
xipere
including
timing
phase
clinical
trial
wet
amd
statements
involve
risks
uncertainties
could
cause
actual
results
differ
materially
reflected
statements
risks
uncertainties
may
cause
actual
results
differ
materially
include
uncertainties
inherent
conduct
clinical
trials
clearside
reliance
third
parties
may
always
full
control
uncertainties
regarding
pandemic
risks
uncertainties
described
clearside
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
march
clearside
quarterly
report
form
quarter
ended
june
filed
sec
august
clearside
periodic
reports
filed
sec
statements
speak
date
press
release
based
information
available
clearside
date
release
clearside
assumes
obligation
intend
update
statements
whether
result
new
information
future
events
otherwise
investor
media
contacts
jenny
kobin
remy
bernarda
ir
source
clearside
biomedical
inc
